Real-World Characteristics, Treatment Patterns, Healthcare Resource Use and Costs of Patients with Diffuse Large B-Cell Lymphoma in the United States
Menée aux Etats-Unis dans un contexte de vie réelle à partir de données portant sur un total de 2 528 patients atteints d'un lymphome diffus à grandes cellules B (âge médian : 72 ans), cette étude rétrospective analyse les stratégies thérapeutiques, l'utilisation des soins médicaux et les coûts associés
Résumé en anglais
Background : Diffuse large B‐cell lymphoma (DLBCL) represents the most common subtype of non‐Hodgkin lymphoma in the US, but current real‐world data is limited. This study was conducted to describe real‐world characteristics, treatment patterns, HRU, and healthcare costs of treated DLBCL patients in the US.
Materials and Methods : A retrospective study was conducted using the Optum ClinformaticsTM Data Mart database (01/2013‐03/2018). Patients with an ICD‐10‐CM diagnosis for DLBCL after October 2015 and no prior ICD‐9‐CM diagnosis for unspecified DLBCL or primary mediastinal large B‐cell lymphoma (PMBCL) where classified as incident; those with such codes were classified as prevalent. An adapted algorithm identified lines of therapy (e.g., 1st line [1L]). All‐cause HRU and costs were calculated per‐patient‐per‐year (PPPY) among patients with a ≥1L.
Results : Among 1,877 incident and 651 prevalent patients with a ≥1L, median age was 72 years and 46% were female. Among incident patients, 22.6% had ≥2L, while 38.4% of prevalent patients had ≥2L. The most frequent 1L therapy was R‐CHOP. Incident patients had 1.3 inpatient and 42.0 outpatient (OP) visits PPPY, while prevalent patients had 0.8 and 31.3 visits PPPY, respectively. Total costs were $137,156 and $81,669 PPPY for incident and prevalent patients, respectively. OP costs were the main driver of total costs at $88,202 PPPY, which were higher within the first year.
Conclusion : This study showed that a large portion of patients require additional therapy after 1L treatment to manage DLBCL, and highlighted the substantial economic burden of DLBCL patients, particularly within the first year following diagnosis.
